Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPU-YL01 in Chronic Hepatitis B
NCT07918456Phase 1Enrolling by invitation
- Sponsor
- Chuangyuan Life Science
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing CPU-YL01 Injection with Placebo Injection (2 arms). Primary endpoints: Adverse Events, Vital Signs and 6 more. Started Jul 2026; status: enrolling by invitation.
02
Drugs
CPU-YL01
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07918456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918456.